Major Response to Imatinib Mesylate in <i>KIT</i>-Mutated Melanoma
F. Stephen Hodi(Harvard University), David E. Fisher(Massachusetts General Hospital)
Cited by 414
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k